IE56026B1
(en)
*
|
1982-10-19 |
1991-03-27 |
Cetus Corp |
Cysteine-depleted muteins of biologically active proteins
|
NZ208309A
(en)
*
|
1983-06-01 |
1988-04-29 |
Hoffmann La Roche |
Recombinant leukocyte, fibroblast, or immune interferons (rifn-#a#, b or #g#) with one cys residue replaced
|
WO1985000817A1
(en)
*
|
1983-08-10 |
1985-02-28 |
Amgen |
Microbial expression of interleukin ii
|
GB8334102D0
(en)
*
|
1983-12-21 |
1984-02-01 |
Searle & Co |
Interferons with cysteine pattern
|
JPS61500790A
(ja)
|
1984-03-28 |
1986-04-24 |
シタス コ−ポレイシヨン |
微生物的に製造されたインターロイキン―2を含有する組成物
|
US4530787A
(en)
*
|
1984-03-28 |
1985-07-23 |
Cetus Corporation |
Controlled oxidation of microbially produced cysteine-containing proteins
|
EP0163603B1
(en)
*
|
1984-05-08 |
1989-12-13 |
Genetics Institute, Inc. |
A human t-cell growth factor
|
GB8412564D0
(en)
*
|
1984-05-17 |
1984-06-20 |
Searle & Co |
Structure and properties
|
US5683688A
(en)
|
1984-05-31 |
1997-11-04 |
Genentech, Inc. |
Unglycosylated recombinant human lymphotoxin polypeptides and compositions
|
NZ212207A
(en)
*
|
1984-05-31 |
1991-07-26 |
Genentech Inc |
Recombinant lymphotoxin
|
US5672347A
(en)
*
|
1984-07-05 |
1997-09-30 |
Genentech, Inc. |
Tumor necrosis factor antagonists and their use
|
CA1275954C
(en)
|
1984-08-31 |
1990-11-06 |
Hing Cheug Wong |
3'-expression enhancing fragments and method
|
IL76360A0
(en)
|
1984-09-26 |
1986-01-31 |
Takeda Chemical Industries Ltd |
Mutual separation of proteins
|
WO1986002068A1
(en)
*
|
1984-09-26 |
1986-04-10 |
Takeda Chemical Industries, Ltd. |
Mutual separation of proteins
|
US4606917A
(en)
*
|
1984-10-03 |
1986-08-19 |
Syntex (U.S.A) Inc. |
Synergistic antiviral composition
|
US4857316A
(en)
*
|
1984-10-03 |
1989-08-15 |
Syntex (U.S.A.) Inc. |
Synergistic antiviral composition
|
US4959314A
(en)
|
1984-11-09 |
1990-09-25 |
Cetus Corporation |
Cysteine-depleted muteins of biologically active proteins
|
US4572798A
(en)
*
|
1984-12-06 |
1986-02-25 |
Cetus Corporation |
Method for promoting disulfide bond formation in recombinant proteins
|
US6107465A
(en)
*
|
1984-12-21 |
2000-08-22 |
Otsuka Pharmaceutical Co., Ltd. |
IL-1β and derivatives thereof and drugs
|
US5342614A
(en)
*
|
1984-12-21 |
1994-08-30 |
Otsuka Pharmaceutical Co., Ltd. |
Method of treating arthritus or inflammation with IL-1β or derivatives thereof
|
DK172052B1
(da)
*
|
1984-12-21 |
1997-09-29 |
Otsuka Pharma Co Ltd |
Antitumor-aktivt stof, fremgangsmåde til dets fremstilling, lægemiddel indeholdende stoffet, gen kodende for stoffet, vektor indeholdende genet samt rekombinant mikroorganisme transformet med en sådan vektor
|
DE3500681A1
(de)
*
|
1985-01-11 |
1986-07-17 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur isolierung und reinigung von lymphokinen
|
US4863849A
(en)
*
|
1985-07-18 |
1989-09-05 |
New York Medical College |
Automatable process for sequencing nucleotide
|
US4810643A
(en)
*
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
US6004548A
(en)
|
1985-08-23 |
1999-12-21 |
Amgen, Inc. |
Analogs of pluripotent granulocyte colony-stimulating factor
|
CA1297003C
(en)
*
|
1985-09-20 |
1992-03-10 |
Jack H. Nunberg |
Composition and method for treating animals
|
US5359035A
(en)
*
|
1985-12-21 |
1994-10-25 |
Hoechst Aktiengesellschaft |
Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
|
AU595864B2
(en)
*
|
1986-03-14 |
1990-04-12 |
Otsuka Pharmaceutical Co., Ltd. |
Il-1 alpha derivatives and drugs
|
US5008374A
(en)
*
|
1986-03-14 |
1991-04-16 |
Otsuka Pharmaceutical Co., Ltd. |
IL-1α derivatives and drugs
|
DE3683910D1
(de)
*
|
1986-09-05 |
1992-03-26 |
Cetus Corp |
Oxidationsresistente muteine von beta-interferon, deren herstellung und diese muteine enthaltende praeparate.
|
JP2526965B2
(ja)
*
|
1987-02-24 |
1996-08-21 |
武田薬品工業株式会社 |
ムテイン,dnaおよびその用途
|
US4987070A
(en)
*
|
1987-03-04 |
1991-01-22 |
Suntory Limited |
Use of a 97 amino acid leader sequence from the E. coli B-galactosidase gene for the production of hanp and hptc as fusion proteins
|
EP0377579A1
(en)
*
|
1987-07-07 |
1990-07-18 |
California Biotechnology, Inc. |
Recombinant fibroblast growth factors
|
JP2602968B2
(ja)
*
|
1987-11-04 |
1997-04-23 |
カリフォルニア バイオテクノロジー インコーポレイテッド |
肺胞の界面活性タンパク類
|
EP0355460B1
(en)
*
|
1988-08-24 |
2000-12-27 |
American Cyanamid Company |
Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization
|
US5079230A
(en)
*
|
1988-09-12 |
1992-01-07 |
Pitman-Moore, Inc. |
Stable bioactive somatotropins
|
CA2003886A1
(en)
*
|
1988-12-16 |
1990-06-16 |
Anthony F. Purchio |
Cloning and expression of simian transforming growth factor-beta 1
|
WO1990008823A1
(en)
*
|
1989-01-31 |
1990-08-09 |
The Upjohn Company |
Somatotropin analogs
|
EP0383599B1
(en)
*
|
1989-02-17 |
1996-02-07 |
Merck & Co. Inc. |
Protein anti-cancer agent
|
US5621078A
(en)
*
|
1989-03-22 |
1997-04-15 |
Merck & Co., Inc. |
Modified pseudomonas exotoxin PE40
|
AU5355790A
(en)
*
|
1989-04-19 |
1990-11-16 |
Cetus Corporation |
Multifunctional m-csf proteins and genes encoding therefor
|
US6207798B1
(en)
|
1989-08-03 |
2001-03-27 |
Merck & Co., Inc. |
Modified PE40 toxin fusion proteins
|
US5173297A
(en)
*
|
1991-07-01 |
1992-12-22 |
Quest International Flavors & Food Ingredients Company Division Of Indopco, Inc. |
Bacteriocin from lactococcus lactis subspecies lactis
|
IL98528A0
(en)
*
|
1990-06-21 |
1992-07-15 |
Merck & Co Inc |
Pharmaceutical compositions containing hybrid for killing bladder cancer cells
|
FR2671554A1
(fr)
*
|
1991-01-11 |
1992-07-17 |
Clonatec Sa |
Peptides synthetiques derivant de l'antigene hbc du virus de l'hepatite b, leurs applications a la detection d'une infection par ce virus et a la vaccination contre l'hepatite b.
|
US5545723A
(en)
*
|
1994-03-15 |
1996-08-13 |
Biogen Inc. |
Muteins of IFN-β
|
US5814485A
(en)
*
|
1995-06-06 |
1998-09-29 |
Chiron Corporation |
Production of interferon-β (IFN-β) in E. coli
|
DE19544167A1
(de)
*
|
1995-11-17 |
1997-05-22 |
Schering Ag |
Verwendung von Interferon-ß zur Behandlung von Bronchialkarzinom bei Bestrahlungstherapie
|
AU6399996A
(en)
*
|
1996-06-19 |
1998-01-07 |
Chiron Corporation |
Bacterial production of interferon-beta using low levels of sodium and potassium ions
|
CN1100875C
(zh)
*
|
1998-03-06 |
2003-02-05 |
上海华晨生物技术研究所 |
新型重组人白细胞介素2的制备方法及其表达载体和工程菌
|
EP2213743A1
(en)
|
2000-04-12 |
2010-08-04 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1935431A3
(en)
|
2000-05-15 |
2008-08-13 |
Health Research, Inc. |
Cancer treatments by using a combination of an antibody against her2 and interleukin-2
|
DE10112825A1
(de)
|
2001-03-16 |
2002-10-02 |
Fresenius Kabi De Gmbh |
HESylierung von Wirkstoffen in wässriger Lösung
|
US6887462B2
(en)
|
2001-04-09 |
2005-05-03 |
Chiron Corporation |
HSA-free formulations of interferon-beta
|
WO2003025541A2
(en)
*
|
2001-09-18 |
2003-03-27 |
Chiron Corporation |
Methods for treating multiple sclerosis
|
KR100511749B1
(ko)
*
|
2001-11-06 |
2005-09-02 |
선바이오(주) |
변형된 인터페론-베타, 및 이의 화학적으로 변형된 배합체
|
ES2500918T3
(es)
|
2001-12-21 |
2014-10-01 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina e interferón beta
|
DE10209822A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
AU2003260393B2
(en)
|
2002-09-11 |
2009-10-01 |
Fresenius Kabi Deutschland Gmbh |
Method of producing hydroxyalkyl starch derivatives
|
WO2004032971A1
(en)
|
2002-10-08 |
2004-04-22 |
Fresenius Kabi Deutschland Gmbh |
Pharmaceutically active oligosaccharide conjugates
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
EP1682180B1
(en)
|
2003-11-04 |
2009-11-04 |
Novartis Vaccines and Diagnostics, Inc. |
Antagonist anti-cd40 monoclonal antibodies and methods for their use
|
US20060234205A1
(en)
*
|
2004-03-05 |
2006-10-19 |
Chiron Corporation |
In vitro test system for predicting patient tolerability of therapeutic agents
|
KR101186821B1
(ko)
|
2004-03-11 |
2012-09-28 |
프레제니우스 카비 도이치란트 게엠베하 |
환원성 아미노화에 의해 제조된, 하이드록시알킬 녹말 및단백질의 접합체
|
JP2008507297A
(ja)
*
|
2004-07-26 |
2008-03-13 |
エンゾン ファーマシューティカルズ,インコーポレーテッド |
最適化されたインターフェロンβ遺伝子
|
GB0523282D0
(en)
|
2005-11-15 |
2005-12-21 |
Isis Innovation |
Methods using pores
|
GB2453377A
(en)
|
2007-10-05 |
2009-04-08 |
Isis Innovation |
Transmembrane protein pores and molecular adapters therefore.
|
EP2070950A1
(en)
|
2007-12-14 |
2009-06-17 |
Fresenius Kabi Deutschland GmbH |
Hydroxyalkyl starch derivatives and process for their preparation
|
ES2382058T3
(es)
|
2008-01-17 |
2012-06-04 |
Philogen S.P.A. |
Combinación de una proteína de fusión de un anticuerpo dirigido contra el EDB de la fibronectina-IL-2, y una molécula de unión a los linfocitos B, progenitores de los linfocitos B y/o sus homólogos cancerosos
|
CN102245760A
(zh)
|
2008-07-07 |
2011-11-16 |
牛津纳米孔技术有限公司 |
酶-孔构建体
|
WO2010004273A1
(en)
|
2008-07-07 |
2010-01-14 |
Oxford Nanopore Technologies Limited |
Base-detecting pore
|
US9077937B2
(en)
*
|
2008-11-06 |
2015-07-07 |
Alcatel Lucent |
Method and apparatus for fast channel change
|
GB0820927D0
(en)
|
2008-11-14 |
2008-12-24 |
Isis Innovation |
Method
|
US9222082B2
(en)
|
2009-01-30 |
2015-12-29 |
Oxford Nanopore Technologies Limited |
Hybridization linkers
|
CN102369298B
(zh)
|
2009-01-30 |
2017-03-22 |
牛津纳米孔技术有限公司 |
跨膜测序中用于核酸构建体的衔接体
|
GB0905140D0
(en)
|
2009-03-25 |
2009-05-06 |
Isis Innovation |
Method
|
CN103460040B
(zh)
|
2011-02-11 |
2016-08-17 |
牛津纳米孔技术有限公司 |
突变型孔
|
WO2012123381A1
(en)
|
2011-03-11 |
2012-09-20 |
Assistance Publique - Hôpitaux De Paris |
Use of low dose il-2 for treating autoimmune - related or inflammatory disorders
|
JP6298404B2
(ja)
|
2011-07-25 |
2018-03-20 |
オックスフォード ナノポール テクノロジーズ リミテッド |
膜貫通ポアを用いる二重鎖ポリヌクレオチド配列決定のためのヘアピンループ方法
|
GB201119244D0
(en)
|
2011-11-08 |
2011-12-21 |
British American Tobacco Co |
Smoking article
|
KR102083695B1
(ko)
|
2012-04-10 |
2020-03-02 |
옥스포드 나노포어 테크놀로지즈 리미티드 |
돌연변이체 리세닌 기공
|
US11155860B2
(en)
|
2012-07-19 |
2021-10-26 |
Oxford Nanopore Technologies Ltd. |
SSB method
|
GB201314695D0
(en)
|
2013-08-16 |
2013-10-02 |
Oxford Nanopore Tech Ltd |
Method
|
US10221450B2
(en)
|
2013-03-08 |
2019-03-05 |
Oxford Nanopore Technologies Ltd. |
Enzyme stalling method
|
GB201313477D0
(en)
|
2013-07-29 |
2013-09-11 |
Univ Leuven Kath |
Nanopore biosensors for detection of proteins and nucleic acids
|
WO2014206899A1
(en)
|
2013-06-25 |
2014-12-31 |
Icm (Institut Du Cerveau Et De La Moelle Épinière) |
Boosting treg cells for treating alzheimer disease and related disorders
|
GB201403096D0
(en)
|
2014-02-21 |
2014-04-09 |
Oxford Nanopore Tech Ltd |
Sample preparation method
|
EP2918285A1
(en)
|
2014-03-11 |
2015-09-16 |
Université Pierre et Marie Curie (Paris 6) |
Interleukin-2 for treating food allergy
|
CN106574300A
(zh)
|
2014-05-02 |
2017-04-19 |
牛津纳米孔技术公司 |
改善目标多核苷酸相对于跨膜孔移动的方法
|
CN117164684A
(zh)
|
2014-09-01 |
2023-12-05 |
弗拉芒区生物技术研究所 |
突变csgg孔
|
WO2016055778A1
(en)
|
2014-10-07 |
2016-04-14 |
Oxford Nanopore Technologies Limited |
Mutant pores
|
GB201418159D0
(en)
|
2014-10-14 |
2014-11-26 |
Oxford Nanopore Tech Ltd |
Method
|
WO2016172445A2
(en)
*
|
2015-04-24 |
2016-10-27 |
The University Of Florida Research Foundation, Inc. |
Methods of identifying biologically active random peptides in plants and libraries of plants expressing candidate biologically active random peptides
|
US10801023B2
(en)
*
|
2015-04-24 |
2020-10-13 |
University Of Florida Research Foundation, Inc. |
Methods of identifying biologically active random peptides in plants and libraries of plants expressing candidate biologically active random peptides
|
US10876109B2
(en)
|
2015-04-24 |
2020-12-29 |
University Of Florida Research Foundation, Inc. |
Methods of identifying biologically active random peptides in prokaryotic cells and libraries of prokaryotic cells expressing candidate biologically active random peptides
|
WO2017068031A1
(en)
|
2015-10-22 |
2017-04-27 |
Iltoo Pharma |
Pharmaceutical compositions of il-2
|
GB201609220D0
(en)
|
2016-05-25 |
2016-07-06 |
Oxford Nanopore Tech Ltd |
Method
|
EP3475413B1
(en)
|
2016-06-22 |
2024-02-14 |
David Klatzmann |
Genetically modified t lymphocytes
|
AU2018234810B2
(en)
|
2017-03-15 |
2023-05-11 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
SG11201909949XA
(en)
|
2017-05-24 |
2019-11-28 |
Pandion Therapeutics Inc |
Targeted immunotolerance
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
EP3752178A1
(en)
|
2018-02-16 |
2020-12-23 |
Iltoo Pharma |
Use of interleukin 2 for treating sjögren's syndrome
|
GB201807793D0
(en)
|
2018-05-14 |
2018-06-27 |
Oxford Nanopore Tech Ltd |
Method
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
US20210236599A1
(en)
|
2018-08-13 |
2021-08-05 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
WO2020102556A1
(en)
|
2018-11-15 |
2020-05-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods of prognosis and classification for preeclampsia
|
MX2021014178A
(es)
|
2019-05-20 |
2022-01-04 |
Pandion Operations Inc |
Inmunotolerancia dirigida a la molecula de adhesion celular de adresina vascular de mucosas (madcam).
|
AU2020401357A1
(en)
|
2019-12-12 |
2022-07-21 |
Assistance Publique - Hôpitaux De Paris |
Interleukin 2 chimeric constructs
|
EP4107187A4
(en)
|
2020-02-21 |
2024-07-03 |
Pandion Operations Inc |
TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
|
CA3166887A1
(en)
|
2020-03-06 |
2021-09-10 |
Gilbert BENSIMON |
Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis
|
US20230159605A1
(en)
*
|
2020-04-29 |
2023-05-25 |
Abion Inc. |
Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant
|
EP4144761A4
(en)
*
|
2020-04-29 |
2024-05-29 |
GenoPharm Inc. |
RECOMBINANT PROTEIN HAVING FUSED INTERFERON-BETA MUTEIN AND ANTIBODY, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
|
EP4412631A1
(en)
|
2021-10-06 |
2024-08-14 |
Iltoo Pharma |
Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
|
WO2024056154A1
(en)
|
2022-09-12 |
2024-03-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Interleukin-2 for use in treating autism spectrum disorder
|
WO2024121173A1
(en)
|
2022-12-05 |
2024-06-13 |
Centre Hospitalier Universitaire De Nimes |
Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis in a subgroup of patients
|